COL4A1相关肾病长期临床过程及肾活检IV型胶原α1链表达评估:一例报告
本文报告一例39岁男性携带COL4A1 p.G1239R杂合变异,表现为持续镜下血尿,10年随访eGFR年均下降1.2 mL/min/1.73 m2。肾活检光镜仅见局灶全球性肾小球硬化及轻度小管扩张;免疫荧光示α1(IV)在肾小管基底膜信号减弱,电镜见GBM局灶变薄及TBM异质性异常。作者结合CLEM分析COL4A1表达,提示血尿伴GBM变薄者除Alport综合征外应警惕COL4A1相关肾病。
要点
- 血尿伴GBM变薄者,鉴别诊断需包括COL4A1相关肾病。
- COL4A1相关肾病可表现为缓慢进展的eGFR下降。
- CLEM半定量评估COL4A1表达或可辅助诊断。
核心结论
- COL4A1相关肾病应纳入血尿伴GBM变薄患者的鉴别诊断,以助系统风险评估与遗传咨询。
- CLEM半定量评估活检标本COL4A1表达可能是携带COL4A1杂合变异者的关键诊断工具。
研究设计与样本
- 单个病例报告:39岁男性,携带COL4A1 p.G1239R杂合变异,随访10年。
- 肾活检行光镜、免疫荧光、电镜及免疫电镜(FluoroNanogold)检查。
- 采用关联光镜与电镜(CLEM)分析COL4A1表达。
主要发现
- 10年随访eGFR年均下降1.2 mL/min/1.73 m2。
- 光镜仅见局灶全球性肾小球硬化及轻度小管扩张。
- 免疫荧光示α1(IV)在肾小管基底膜信号强度减弱。
- 电镜示GBM局灶变薄及TBM异质性异常(变薄、局灶增厚、网状化、层状化)。
- 免疫电镜示TBM金颗粒密度降低,与荧光强度相关。
临床怎么用
- 对血尿伴GBM变薄者,除Alport综合征外应考虑COL4A1相关肾病。
- 对怀疑COL4A1相关肾病者,可考虑CLEM半定量评估活检标本COL4A1表达。
局限性
- 单例病例报告,结论的普遍性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COL4A1 variants cause a spectrum of systemic disorders encompassed by Gould syndrome. While kidney involvement is recognized, its long-term progression and detailed kidney pathology remain uncharacterized. We present a 39-year-old man with a heterozygous p.G1239R COL4A1 variant, persistent microscopic hematuria, and a progressive estimated glomerular filtration rate decline of -1.2 mL/min/1.73 m2 per year over a 10-year follow-up. Light microscopy showed only focal global glomerulosclerosis and mild tubular dilatation. Immunofluorescence for the α1 chain of type IV collagen (α1[IV]) revealed reduced signal intensity in the tubular basement membrane (TBM). Electron microscopy demonstrated focal thinning of the glomerular basement membrane (GBM) and heterogeneous abnormalities, including thinning, focal thickening, reticulation, and lamellation, of the TBM. Immunoelectron microscopy using FluoroNanogold showed decreased density of gold particles in the TBM, correlating with the fluorescence intensity. This report analyzes COL4A1 expression using correlative light and electron microscopy (CLEM), and describes the long-term kidney function decline. In patients with hematuria and a thin GBM, in addition to Alport syndrome, COL4A1-associated nephropathy should also be considered. Recognizing this entity is essential for accurate systemic risk assessment and genetic counseling. Semi-quantitative assessment of COL4A1 expression in biopsy specimens using CLEM may be a key diagnostic tool for patients with heterozygous COL4A1 variants.
引用
- Yoshida R, Hashiguchi A, Nakayama T, et al. Long-Term Clinical Course of COL4A1-Associated Nephropathy and Assessment of α1 Chain of Type IV Collagen Expression in Kidney Biopsy Specimens: A Case Report. Am J Kidney Dis. 2026. PMID: 42497975. doi:10.1053/j.ajkd.2026.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。